Tumor-targeted MR contrast agents: hype or future hope?
Reimer
Peter
P
Department of Radiology, Klinikum Karlsruhe, Academic Teaching Hospital of the University of Freiburg, Moltkestrasse 90, D-76133 Karlsruhe, Germany. peter.reimer@klinik.uni-karlsruhe.de
D000818:Animals; D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood; D003287:Contrast Media / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics; D004578:Electron Spin Resonance Spectroscopy / Q000639:trends; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000639:trends; D009369:Neoplasms / Q000175:diagnosis* / Q000378:metabolism*; D011092:Polyethylene Glycols / Q000378:metabolism / Q000493:pharmacokinetics; D011856:Radiographic Image Enhancement / Q000639:trends; D011956:Receptors, Cell Surface / Q000096:biosynthesis*; D013501:Surface-Active Agents / Q000378:metabolism / Q000493:pharmacokinetics; D014018:Tissue Distribution / Q000187:drug effects
D014408:Biomarkers, Tumor; D003287:Contrast Media; D011956:Receptors, Cell Surface; D013501:Surface-Active Agents; C027786:glucose receptor; D011092:Polyethylene Glycols